Gain‐of‐function mutations (e.g., D374Y, S127R) amplify PCSK9 activity, causing autosomal dominant hypercholesterolemia (LDL‐C > 190 mg/dL) and accelerating atherosclerosis progression. This evidence concerns the gene PCSK9 and atherosclerosis.